SG10201902609TA - Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same - Google Patents

Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same

Info

Publication number
SG10201902609TA
SG10201902609TA SG10201902609TA SG10201902609TA SG10201902609TA SG 10201902609T A SG10201902609T A SG 10201902609TA SG 10201902609T A SG10201902609T A SG 10201902609TA SG 10201902609T A SG10201902609T A SG 10201902609TA SG 10201902609T A SG10201902609T A SG 10201902609TA
Authority
SG
Singapore
Prior art keywords
salt
containing compound
novel nitrogen
manufacturing
same
Prior art date
Application number
SG10201902609TA
Other languages
English (en)
Inventor
Hirofumi Fukunaga
Sachiko Shinjo
Daisuke Nakagawa
Shinichiro Sekine
Takayuki Yamakawa
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of SG10201902609TA publication Critical patent/SG10201902609TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D255/00Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08Copper compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201902609TA 2015-03-25 2016-03-25 Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same SG10201902609TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015062306 2015-03-25

Publications (1)

Publication Number Publication Date
SG10201902609TA true SG10201902609TA (en) 2019-04-29

Family

ID=56977546

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707899SA SG11201707899SA (en) 2015-03-25 2016-03-25 Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
SG10201902609TA SG10201902609TA (en) 2015-03-25 2016-03-25 Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201707899SA SG11201707899SA (en) 2015-03-25 2016-03-25 Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same

Country Status (24)

Country Link
US (3) US20180008583A1 (ru)
EP (3) EP4059936A1 (ru)
JP (1) JP6411634B2 (ru)
KR (1) KR102029746B1 (ru)
CN (2) CN107428755B (ru)
AU (4) AU2016237099C1 (ru)
BR (1) BR112017020484B1 (ru)
CA (1) CA2980268C (ru)
CO (1) CO2017010806A2 (ru)
CY (1) CY1124387T1 (ru)
DK (1) DK3275883T3 (ru)
ES (1) ES2877707T3 (ru)
HR (1) HRP20211031T1 (ru)
HU (1) HUE059670T2 (ru)
IL (4) IL254532B (ru)
LT (1) LT3275883T (ru)
MX (3) MX2017012184A (ru)
PL (1) PL3275883T3 (ru)
PT (1) PT3275883T (ru)
RS (1) RS62165B1 (ru)
RU (2) RU2720989C2 (ru)
SG (2) SG11201707899SA (ru)
SI (1) SI3275883T1 (ru)
WO (1) WO2016153054A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6215335B2 (ja) 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
EP4159727A1 (en) 2017-02-28 2023-04-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
PE20211640A1 (es) 2018-08-29 2021-08-24 Morphic Therapeutic Inc INHIBICION DE LA INTEGRINA xvß6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
JP2022523947A (ja) * 2019-03-11 2022-04-27 バイオコンパティブルズ ユーケー リミテッド 中枢神経系腫瘍の治療方法
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
WO2022136317A1 (en) 2020-12-21 2022-06-30 Advanced Accelerator Applications International Sa Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5941386B2 (ja) 1977-01-14 1984-10-06 株式会社紀文 高蛋白水産練製品様食品の製法
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE69736812T2 (de) 1996-11-27 2007-08-09 Bristol-Myers Squibb Pharma Co. Neue integrin rezeptor antagonisten
BR9813769A (pt) * 1997-12-17 2000-10-10 Merck & Co Inc Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste.
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
DE69936148T2 (de) * 1998-12-18 2008-01-24 Bristol-Myers Squibb Pharma Co. Vitronektinrezeptorantagonist-arzneimittel
US6511648B2 (en) * 1998-12-18 2003-01-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
JP2003520271A (ja) 2000-01-24 2003-07-02 メルク エンド カムパニー インコーポレーテッド αvインテグリン受容体拮抗薬
AU2001270025B2 (en) * 2000-06-21 2005-08-18 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
JP4615826B2 (ja) 2001-01-29 2011-01-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
KR101383655B1 (ko) 2010-05-24 2014-04-10 주식회사 바이오이미징코리아 트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물
FR2968999B1 (fr) * 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) * 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
WO2013048996A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Method for the purification of a peptide-based imaging agent precursor
PT2840080T (pt) * 2012-04-17 2018-02-06 Fujifilm Corp Composto heterocíclico que contém azoto ou sal do mesmo
FR3001154B1 (fr) * 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
JP6215335B2 (ja) * 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体

Also Published As

Publication number Publication date
RU2720989C2 (ru) 2020-05-15
IL283289A (en) 2021-07-29
EP3275883A1 (en) 2018-01-31
PT3275883T (pt) 2021-07-07
JPWO2016153054A1 (ja) 2018-04-19
KR102029746B1 (ko) 2019-10-08
ES2877707T3 (es) 2021-11-17
IL283224B (en) 2022-02-01
CN107428755A (zh) 2017-12-01
EP3275883B1 (en) 2021-06-02
CY1124387T1 (el) 2022-07-22
SI3275883T1 (sl) 2021-09-30
IL283224A (en) 2021-07-29
BR112017020484A2 (pt) 2018-07-03
IL254532A0 (en) 2017-11-30
AU2016237099C1 (en) 2023-01-19
AU2016237099A1 (en) 2017-10-19
RU2020115068A (ru) 2020-06-26
AU2019246859A1 (en) 2019-10-31
AU2020244578A1 (en) 2020-11-05
CN107428755B (zh) 2020-03-03
AU2016237099B2 (en) 2019-11-07
MX2017012184A (es) 2018-01-09
AU2020244580B2 (en) 2022-08-11
HRP20211031T1 (hr) 2021-10-01
EP4059936A1 (en) 2022-09-21
EP3872079A1 (en) 2021-09-01
MX2023005703A (es) 2023-05-29
RU2017133107A (ru) 2019-04-25
EP3275883A4 (en) 2018-03-07
JP6411634B2 (ja) 2018-10-24
RU2767398C2 (ru) 2022-03-17
IL283289B (en) 2022-02-01
HUE059670T2 (hu) 2022-12-28
PL3275883T3 (pl) 2021-11-15
SG11201707899SA (en) 2017-10-30
DK3275883T3 (da) 2021-06-28
CA2980268A1 (en) 2016-09-29
LT3275883T (lt) 2021-08-25
US20180008583A1 (en) 2018-01-11
US20210015802A1 (en) 2021-01-21
US20240108607A1 (en) 2024-04-04
IL283288A (en) 2021-07-29
RU2020115068A3 (ru) 2020-08-17
CO2017010806A2 (es) 2018-01-16
CN111171026B (zh) 2023-03-03
AU2020244580A1 (en) 2020-11-05
CA2980268C (en) 2021-10-26
AU2020244578B2 (en) 2022-08-11
MX2023005704A (es) 2023-05-29
WO2016153054A1 (ja) 2016-09-29
IL254532B (en) 2021-12-01
BR112017020484B1 (pt) 2023-03-28
IL283288B (en) 2022-02-01
CN111171026A (zh) 2020-05-19
AU2019246859B2 (en) 2020-07-02
RU2017133107A3 (ru) 2019-04-25
KR20170117577A (ko) 2017-10-23
RS62165B1 (sr) 2021-08-31

Similar Documents

Publication Publication Date Title
SG10201902609TA (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
SA518400053B1 (ar) عملية مُحسنة لإنتاج حمض أكريليك
MX2019012927A (es) Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparacion.
PH12016502334A1 (en) Method for producing fused heterocyclic compound
MX2018003311A (es) Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario.
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
WO2018029711A3 (en) Process for the preparation of venetoclax
MX2020008507A (es) Metodo para producir 1,1,3,3-tetracloropropeno.
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
MX2021003070A (es) Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino.
IL278932A (en) Process for the synthesis of (S)-3-amino-4-(difluoromethylnyl)cyclopent-1-ene-1-carboxylic acid
EA202090933A1 (ru) Способ получения гербицидных соединений пиридазинона
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2022002017A (es) Metodo para producir derivado de heterociclideno acetamida.
MX2019004024A (es) Metodo para preparar acetofenonas sustituidas con ciclopropilo.
EP3838381C0 (en) METHOD FOR PRODUCING AMMONIUM THIOSULFATE
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives
PH12019500484A1 (en) Optimized production method for pest control agent
MX2021001530A (es) Metodo de produccion de esteres carbonicos.
PH12018502377B1 (en) Process for the manufacture of 6-alkynyl-pyridine derivatives
MX2019000984A (es) Proceso para preparacion de indanonas.
EA201892406A1 (ru) Способ получения гербицидных пиридинилимидазолоновых соединений
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.
MX2021014245A (es) Procedimientos y productos intermedios para preparar un inhibidor de btk.
MX2021012690A (es) Formas cristalinas y metodos para producir formas cristalinas de un compuesto.